Objective To systematically review the unfavorable treatment outcome of multidrug-resistant tuberculosis in China. Methods CNKI, WanFang Data, CBM, PubMed, EMbase, and Web of Science databases were electronically searched to collect studies that reported unfavorable treatment outcomes of multidrug-resistant tuberculosis in China from inception to April 2021. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of included studies. Meta-analysis was then performed by using Stata 12.0 software. Results A total of 11 studies involving 4 465 patients were included. The results of meta-analysis showed that the overall rate of treatment success was 62% (95%CI 55% to 70%), the rate of treatment failure was 19% (95%CI 12% to 26%), the rate of default was 7% (95%CI 4% to 10%), the rate of mortality was 6% (95%CI 4% to 8%) and the rate of unfavorable treatment outcome was 25% (95%CI 19% to 32%). Conclusions Current evidence shows that the treatment failure rate of multidrug-resistant tuberculosis in China is slightly high. Due to limited quality and quantity of the included studies, more high-quality studies are required to verify the above conclusions.
LIU Junping, SUN Yanbo, ZHANG Shulan, GUAN Li, LIU Zhixin, SUN Minglei, ZHAO Juan, WANG Chen, ZOU Dandan, LIANG Libo. Unfavorable treatment outcome of multidrug-resistant tuberculosis in China: a meta-analysis. Chinese Journal of Evidence-Based Medicine, 2021, 21(10): 1174-1178. doi: 10.7507/1672-2531.202106123